BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Agendia and Genecast Biotech enter into a partnership

19 September 2018 | News

Agendia and Genecast will co-present key data supporting the MammaPrint and BluePrint tests at a satellite symposium during the Chinese Society of Clinical Oncology (CSCO) Annual Meeting on Friday 21 September at 5:30 PM Beijing time, entitled "Breast Cancer Precision Medicine Symposium."

Agendia, Inc., a world leader in precision oncology has announced that it has entered into an exclusive commercial partnership with Genecast Biotechnology Co., a Beijing-based cancer testing and diagnostics company, to offer the MammaPrint and BluePrint breast cancer risk of recurrence and molecular subtyping tests to patients and their physicians in China for the first time. Under the terms of the agreement, Genecast will hold exclusive marketing and access rights to offer MammaPrint and BluePrint testing in China.

Agendia and Genecast will co-present key data supporting the MammaPrint and BluePrint tests at a satellite symposium during the Chinese Society of Clinical Oncology (CSCO) Annual Meeting on Friday 21 September at 5:30 PM Beijing time, entitled "Breast Cancer Precision Medicine Symposium." Speakers will include Dr. Zefei Jiang, Director of Breast Cancer, Chief Physician and Professor at the Affiliated Hospital of Academy of Military Medical Sciences and Dr. Shu Wang, Director of Breast Disease Center and Professor of General Surgery at Peking University People's Hospital.

Breast cancer is the most common cancer among women in China with roughly 300,000 women diagnosed each year. This number is expected to increase as screening methods improve and a greater percentage of the population gains access to these tools, leading to more cancers detected at an early stage. At launch later this year, physicians will be able to send their patients' samples to Genecast's specialty oncology laboratory for MammaPrint and BluePrint testing.

MammaPrint and BluePrint provide essential genomic information which, when added to clinical factors such as age, tumor size and hormone receptor status, help physicians make informed treatment management decisions, reducing the risk of potential overtreatment and the associated side effects to provide the best outcome for each patient. This has significant quality of life and cost-effectiveness benefits for patients and for reducing healthcare spend on a national scale.

Dr. Franklin Libenson, Senior Vice President Strategic Marketing and Market Development at Agendia, said 'China is a

significant market with an urgent need for tests like MammaPrint and BluePrint which can be performed domestically and are backed by both the highest level of clinical evidence (Level 1A) and prestigious international breast cancer treatment guidelines. We believe that patients should have access to the precision answers our tests provide and, in partnering with Genecast, we are now able to be the first to offer them to women with breast cancer and their care team in China."

Du Bo, Co-Founder and CEO at Genecast, said "At Genecast, we are dedicated to improving cancer treatment through precision cancer diagnostics. We recognize the value of MammaPrint and BluePrint in enabling a unique, personalized approach to treating early-stage breast cancer and are very pleased to deliver these tests in China. Cancer is fundamentally a genomic disease, by applying cutting-edge tools that analyze the genes of a person's tumor we can better understand it and act more effectively to prevent over and under treatment."

Agendia's MammaPrint test analyzes 70 genes most associated with breast cancer recurrence to provide a clear, binary Low or High Risk of distant recurrence result, while BluePrint analyzes 80 genes, which classify a patient's breast cancer into functional molecular subtypes.

The landmark MINDACT trial, published in the *New England Journal of Medicine* in 2016, found that almost 50 percent of patients initially identified with a high risk of their cancer recurring based on clinical and pathological factors and thus candidates for chemotherapy, were in fact low risk according to the MammaPrint test and unlikely to benefit from it. The results of the MINDACT trial have the potential to spare more than 100,000 women annually with early-stage breast cancer worldwide from unnecessary toxicities and side effects from chemotherapy as well as creating considerable cost savings.